Skip to main
DHR
DHR logo

Danaher (DHR) Stock Forecast & Price Target

Danaher (DHR) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 47%
Buy 41%
Hold 12%
Sell 0%
Strong Sell 0%

Bulls say

Danaher demonstrates a strong positive outlook supported by an increase in performance obligations from $4.5 billion in 1Q25 to $4.9 billion in 2Q25, which indicates robust demand for its products. The company is confident in achieving a growth rate of approximately 4.5% in its Life Sciences segment during 4Q25, driven by favorable comparisons in genomics and successful new product launches. Additionally, the expected revenue from Cepheid Respiratory, estimated between $300 million to $500 million in the upcoming quarters, further highlights the potential for substantial earnings growth amidst a strong operational performance.

Bears say

Danaher's anticipated recognition of 46% of its 2Q25 obligations as revenue within the next 12 months represents a decline from the previous quarter's 48%, indicating weakening short-term revenue growth prospects. The company faces significant risks stemming from geopolitical disruptions, foreign exchange volatility, potential underperformance in critical high-growth markets, particularly in China, and revisions to projected end-market growth rates. Furthermore, despite a slightly below-expected revenue guidance for Biotechnology and Life Sciences in 3Q25, confidence in the second half is tempered by uncertainties in macroeconomic conditions and market recovery.

Danaher (DHR) has been analyzed by 17 analysts, with a consensus rating of Buy. 47% of analysts recommend a Strong Buy, 41% recommend Buy, 12% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Danaher and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Danaher (DHR) Forecast

Analysts have given Danaher (DHR) a Buy based on their latest research and market trends.

According to 17 analysts, Danaher (DHR) has a Buy consensus rating as of Nov 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $246.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $246.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Danaher (DHR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.